Burrard Pharmaceuticals supports importers and distributors seeking amoxicillin finished-dose supply through a partner-site model. We are headquartered in Vancouver, Canada. We do not manufacture in-house. Manufacture for this programme is placed with a qualified partner GMP site named under CDA.
Programme quality evidence (site GMP certificates, API documentation as applicable) is shared in the quality pack under CDA. Site GMP status is not the same as product marketing authorisation in your destination market.
This page discusses the International Nonproprietary Name (INN) amoxicillin. Innovator or local brand names are referenced for identification only and are not Burrard trademarks or Burrard-branded goods.
This programme covers amoxicillin (plain). Amoxicillin–clavulanate (co-amoxiclav) is out of scope unless separately confirmed under CDA.
Request amoxicillin quality packPublic attributes only. Strengths, packs, and stability are confirmed under CDA.
| INN | Amoxicillin |
| Dosage form(s) | Capsules and/or tablets — confirmed under CDA / quality pack |
| Strengths | Confirmed under CDA / quality pack |
| Pack sizes | Confirmed under CDA / quality pack |
| Stability / climate zone | Climate-zone / stability data as available for the named pack and site — request quality pack. |
| Dossier format | CTD / ACTD availability confirmed per programme under CDA |
| Facility class | Facility class confirmed in quality pack for named site |
| WHO-PQ | Not claimed on this page |
| BE / bioequivalence | Not claimed — Burrard does not hold BE |
| MOQ / Incoterms | Confirmed under CDA |
Burrard coordinates amoxicillin finished-dose supply programmes for qualified commercial partners. Manufacture is performed at a qualified partner GMP site — [Partner site — named under CDA] — not at a Burrard-owned plant.
We support a docs-first qualification path: request the amoxicillin quality pack, review site and batch evidence under CDA, then book a short supply call on territory options.
Typical contents as available per programme (confirmed under CDA):
A quality pack is a qualification package for B2B partners. It is not a marketing authorisation, product approval letter, or patient information leaflet.
Site GMP or API documentation for a named partner site describes the manufacturing site or API, not Burrard product approval in any destination market (including the United States, European Union, or Canada). Local registration and MA ownership follow the importer or MAH path for that territory.
No. Burrard does not manufacture in-house. For the amoxicillin finished-dose programme, manufacture is placed with a qualified partner GMP site named per programme under CDA. Site identity and certificates are shared in the quality pack after CDA.
Burrard does not claim product FDA approval, Health Canada approval, or EMA approval for amoxicillin on this page. Destination-market marketing authorisation is market-specific and is typically held by the local MAH or importer. Site or API programme evidence shared in a quality pack is not the same as product marketing authorisation.
Strengths, dosage forms (capsules and/or tablets), and packs are confirmed under CDA and in the quality pack for the named partner configuration.
No. This programme covers amoxicillin only. Amoxicillin-clavulanate is a separate programme if offered later under CDA.
Climate-zone and stability data as available for the named pack and site are provided via the quality pack. Unverified shelf-life claims are not published on the product page.
The amoxicillin partner-supply page does not claim WHO prequalification. Any WHO-related certificate language must match the exact certificate for the named site or SKU after regulatory verification.
Email bd@burrardpharma.com with your company, territory, and whether you need finished-dose supply, dossier support, or both. Burrard will outline CDA, the amoxicillin quality pack, and a short supply call.
No. Burrard does not hold bioequivalence claims for this programme. Local BE or biowaiver requirements remain part of the registration pathway in the destination market.
A short supply call is arranged by email after CDA. Include company, country, and whether you need finished-dose supply, dossier support, or both.